The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab or placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: An updated analysis of KEYNOTE-859 for patients enrolled in Asia.
 
Chia Jui Yen
No Relationships to Disclose
 
Do-Youn Oh
Consulting or Advisory Role - Abbvie; Alligtor Bioscience AB; Arcus Biosciences; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Eutilex; Genentech/Roche; Halozyme; Hana Pharm; Idience; IQVIA; J-Pharma; LG Chem; Merck Serono; Mirati Therapeutics; Moderna Therapeutics; MSD Oncology; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Yuxian Bai
No Relationships to Disclose
 
Min-Hee Ryu
Honoraria - Astellas Pharma; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Daiichi Sankyo; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Daiichi Sankyo; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst)
 
Jeeyun Lee
Consulting or Advisory Role - AstraZeneca; Guardant Health AMEA; Mirati Therapeutics; Oncologie; Trutino Biosciences
Research Funding - AstraZeneca; Merck Sharp & Dohme
 
Jin Li
Employment - Shanghai Gobroad Cancer Hospital
Leadership - Shanghai Gobroad Cancer Hospital
Speakers' Bureau - AstraZeneca; Lilly
 
Lin Yang
No Relationships to Disclose
 
Hisateru Yasui
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; JMS; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Hiroshi Yabusaki
No Relationships to Disclose
 
Ka On Lam
Honoraria - Amgen; Bayer; Daiichi Sankyo; Innovent Biologics; Merck; MSD; Pierre Fabre; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Fosun Pharma; GlaxoSmithKline; MSD; Pierre Fabre
Speakers' Bureau - MSD
Travel, Accommodations, Expenses - Taiho Pharmaceutical
 
Kensei Yamaguchi
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Taiho Pharmaceutical
 
Kun-Huei Yeh
Honoraria - Amgen; Bristol-Myers Squibb; Daiichi Sankyo; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; TTY Biopharm
Consulting or Advisory Role - AstraZeneca; Bayer; Daiichi Sankyo; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; DSI/AZ; MSD; MSD; Novartis; Pfizer; Pierre Fabre; Takeda
Travel, Accommodations, Expenses - Ono Pharmaceutical; Pfizer; Takeda
 
Lina Yin
Employment - Merck
Honoraria - Merck
Travel, Accommodations, Expenses - Merck
 
Pierre Leconte
Employment - MSD Oncology
Stock and Other Ownership Interests - MSD Oncology
Travel, Accommodations, Expenses - MSD Oncology
 
Pooja Bhagia
Employment - Merck
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Daiichi Sankyo; Eisai; indivumed; LG Chem; MSD Oncology; Ono Pharmaceutical; Toray Industries
Speakers' Bureau - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; BMS/Ono; Daiichi Sankyo/UCB Japan; Eisai; MSD Oncology
Research Funding - Amgen (Inst); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daichii Sankyo; Eisai; Indivumed; Lilly; MSD Oncology; Roche/Genentech; Sillajen; Zymeworks